research
Gut Bacteria Changed How Long a Cancer Drug Stayed in Circulation
Preclinical studies linked microbiome shifts to slower liver clearance and greater tumor delivery of nanoparticle chemotherapy.
Summary
Preclinical studies linked microbiome shifts to slower liver clearance and greater tumor delivery of nanoparticle chemotherapy.
MD Anderson researchers found that metronidazole reshaped gut bacteria, bile acids and liver Kupffer-cell activity in preclinical models, roughly doubling the circulation time of a nanoparticle chemotherapy and increasing tumor accumulation. A fecal microbiota transfer reproduced key effects without antibiotics across models of colon, breast, melanoma and pancreatic cancers. The work is preclinical and does not establish a treatment regimen for people.
Why it matters
Preclinical studies linked microbiome shifts to slower liver clearance and greater tumor delivery of nanoparticle chemotherapy.
Limits and context
- MD Anderson researchers found that metronidazole reshaped gut bacteria, bile acids and liver Kupffer-cell activity in preclinical models, roughly doubling the circulation time of a nanoparticle chemotherapy and increasing tumor accumulation.
- The work is preclinical and does not establish a treatment regimen for people.
Key claims
Preclinical studies linked microbiome shifts to slower liver clearance and greater tumor delivery of nanoparticle chemotherapy.
Qualification: MD Anderson researchers found that metronidazole reshaped gut bacteria, bile acids and liver Kupffer-cell activity in preclinical models, roughly doubling the circulation time of a nanoparticle chemotherapy and increasing tumor accumulation.
Evidence: source-2026-08-01-007
Sources
- MD Anderson via Newswise: Microbiome and nanoparticle chemotherapyUniversity of Texas MD Anderson Cancer Center via Newswise · official announcement
Corrections
No corrections have been recorded for this story.